大疱性类天疱疮（Bullous Pemphigoid, BP）是一好发于老年人的自身免疫性大疱性皮肤病，皮损常表现为水肿性红斑基础上的水疱和大疱，并伴有严重的瘙痒，患者血清中可检测到抗BP180和（或）BP230的IgG型抗体。目前对于大疱性类天疱疮的治疗多依赖于糖皮质激素等免疫抑制剂的系统应用，但是长期大剂量系统应用糖皮质激素会带来很多副作用，导致患者的死亡率居高不下。本课题组自2007年开始对BP患者进行外用糖皮质激素治疗，并取得了很好的疗效，但其中有一部分患者，其循环中存在有抗BP230的IgE型抗体与大量的嗜酸性粒细胞，对外用药物治疗存在抵抗。因此本课题将从这一临床观察入手，在前期工作的基础上，对BP230特异性IgE型抗体的功能及其与嗜酸性粒细胞的相互作用进行研究，明确抗BP230 IgE型抗体在BP发病机制中的作用，为难治性BP患者的治疗寻找新靶点。

Bullous Pemphigoid is an autoimmune bullous disease that often happened to elderly people, which presents as blister and bulla on the urticarial base with severe pruritus. The IgG antibodies against BP180 and (or) BP230 can be detected in the sera of BP patients. Most of the treatments depend on systemic application of corticoid, which will lead to amount of side-effects and high mortality. Our group started topical corticoid treatment for BP patients since 2007, and achieved good results. But some of the patients that have anti-BP230 IgE antibody and high level of eosinophils showed resistance to topical treatment. In this project, we will start from this clinical observation and base on the previous results, study the function of anti-BP230 IgE and the relationship between the antibody and eosinophils, elucidating the role of anti-BP230 IgE and further look for the new target for the treatment of refractory BP patients.